Alumis (ALMS) Current Deferred Revenue (2025 - 2026)
Alumis' (ALMS) quarterly Current Deferred Revenue came in at $6.7 million in Q2 2026, up 357.41% quarter-over-quarter from $1.5 million in Q4 2025.
Powered by 
Analysis
Alumis (ALMS) Current Deferred Revenue (2025 - 2026) Analysis & Trends
Alumis (ALMS) has reported Current Deferred Revenue for 2 consecutive years, with $6.7 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $6.7 million in Q2 2026; TTM through Jun 2026 was $6.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.5 million, changed N/A from the prior year.
- Current Deferred Revenue was $6.7 million for Q2 2026 at Alumis, up from $1.5 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $6.7 million in Q2 2026 and troughed at $1.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Alumis | 966.94 Mn | 464.65 Mn | - |